Evidence map›Paper›PMID 39334061›Full record

ArticleBMC cancer2024

Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.

Wenxin Ding, Tian Xu, Hui Xiang, Jing Liang, Weiwei Liang, Nan Xiang, Jingsheng Zhao, Guoyin Li, Zewen Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenxin Ding *Department of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China.
Tian Xu *Department of Oncology, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China.
Hui Xiang *Department of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China.
Jing LiangDepartment of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Ji Shou University, Jishou, China.
Weiwei LiangDepartment of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Ji Shou University, Jishou, China.
Nan XiangDepartment of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Ji Shou University, Jishou, China.
Jingsheng ZhaoDepartment of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Ji Shou University, Jishou, China.
Guoyin LiDepartment of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China. ligy@zknu.edu.cn.
Zewen SongDepartment of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China. xy3songzw@csu.edu.cn.

Funding

the Wisdom Gathering and Talent Cultivating Program from the Third Xiangya Hospital YX202211
6 · The paper itself

Abstract

backgroundA dosimetric evaluation is still lacking in terms of clinical target volume (CTV) omission in stage III patients treated with 4D-CT Intensity-Modulated Radiation Therapy (IMRT).

methods49 stage III NSCLC patients received 4D-CT IMRT were reviewed. Target volumes and organs at risk (OARs) were re-delineated. Four IMRT plans were conducted retrospectively to deliver different prescribed dose (74 Gy-60 Gy), and with or without CTV implementation. Dose and volume histogram (DVH) parameters were collected and compared.

resultsIn the PTV-g 60 Gy plan (PTV-g refers to the PTV generated from the internal gross tumor volume), only 5 of 49 patients had the isodose ≥ 50 Gy line covering at least 95% of the PTV-c (PTV-c refers to the PTV generated from the internal CTV) volume. When the prescribed dose was elevated to 74 Gy to the PTV-g, 33 of 49 patients could have the isodose ≥ 50 Gy line covering at least 95% of the PTV-c volume. In terms of OARs protection, the SIB-IMRT plan showed the lowest value of V5, V20, and mean dose of lung, had the lowest V55 of esophagus, and the lowest estimated radiation doses to immune cells (EDIC). The V20, V30, and mean dose of heart was lower in the simultaneous integrated boost (SIB) IMRT (SIB-IMRT) plan than that of the PTV-c 60 Gy plan.

conclusionsCTV omission was not suitable for stage III patients when the prescribed dose to PTV-g was 60 Gy in the era of 4D-CT IMRT. CTV omission plus high dose to PTV-g (74 Gy for example) warranted further exploration. The SIB-IMRT plan had the best protection to normal tissue including lymphocytes, and might be the optimal choice.

Indexed as

Carcinoma, Non-Small-Cell LungFour-Dimensional Computed TomographyLung NeoplasmsOrgans at RiskRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective Studies4D-CTCTV omissionEDICIMRTNSCLC

Identifiers

PMID39334061
PMCPMC11438206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.